the product in the database has an inactive status
indications:
The use of FEIBs is indicated only in patients with high factor VIII inhibitor over 10 Bethesda units / ml in cases of haemorrhage and haemorrhage. The preparation should be administered after prior consultation with a doctor who has experience in its use. Good clinical effect is not always obtained. Insufficient effect is usually observed in the case of massive postoperative bleedings. The preparation is most often used in patients with haemophilia A with factor VIII inhibitor (10-15% of all hemophilia patients in Poland) as well as in patients with acquired factor VIII inhibitor. It has also been used in patients with massive bleeding and the presence of factor IX inhibitors.
Composition:
The activity of the preparation is always indicated on the packaging. 1 unit corresponds to the amount of activated prothrombin complex, which in the presence of factor VIII inhibitor or deficiency of this factor will correct the partial thromboplastin time to 35 seconds.
Action:
Concentrate of activated prothrombin complex agents, obtained from a pool of pooled plasma from many healthy and controlled in terms of carriers (HBV, HCV and HIV 1) donors. In order to eliminate possible viruses and reduce the risk of infection, additional thermal inactivation of viruses in the preparation (steam) is applied. The exact mechanism of action has not been elucidated. FEIBA (Factor Eight Inhibitors of Bypassing Activity) bypasses the action of the factor VIII inhibitor. Although the substances responsible for the clinical effect have not been accurately identified, it is known that this formulation contains activators and precursors of prothrombin coagulation factors (dependent on vitamin K), including activated factor VII and factor X.
Contraindications:
Patients with a high risk of embolism - thrombotic disease (myocardial infarction, etc.) can receive this preparation only in situations of immediate life threat.
Precautions:
Pregnancy and lactation:
Side effects:
Complications thromboembolic especially after very high doses of the drug. Less serious side effects: breakdown, fever, urticaria, nausea and chills. They can be prevented by administration of antihistamines and steroids prior to infusion. This preparation can sometimes cause a drop in blood pressure. Exceptional caution is required when using the preparation in neonates and in people with hepatic impairment. The methods of virus inactivation, similar to those of factor VIII and IX, do not fully eliminate the risk of transmission of viral diseases.
Dosage:
Treatment always adapts to the specific clinical situation, taking into account the highest and current values of the inhibitor titre. The most frequent administration is 50-100 IU / kg, but not more than 200 IU / kg m.c. In order to properly prepare the injection for injection, carefully read the manufacturer's instructions. There is no method that allows objective laboratory monitoring of treatment. In assessing the effectiveness of the preparation, we are primarily guided by clinical symptoms (bleeding episode). Therefore, in cases of massive life-threatening bleeding or need for surgery, treatment should be carried out by a physician experienced in the use of FEIB.
(C)
